1. Home
  2. SCOR vs MURA Comparison

SCOR vs MURA Comparison

Compare SCOR & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo comScore Inc.

SCOR

comScore Inc.

HOLD

Current Price

$7.08

Market Cap

32.8M

ML Signal

HOLD

Logo Mural Oncology plc

MURA

Mural Oncology plc

HOLD

Current Price

$2.04

Market Cap

36.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCOR
MURA
Founded
1999
2013
Country
United States
Ireland
Employees
N/A
N/A
Industry
Business Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
32.8M
36.0M
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
SCOR
MURA
Price
$7.08
$2.04
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$6.00
AVG Volume (30 Days)
16.5K
218.9K
Earning Date
11-04-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$358,940,000.00
N/A
Revenue This Year
$2.01
N/A
Revenue Next Year
$1.57
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.77
N/A
52 Week Low
$4.39
$0.95
52 Week High
$10.18
$4.74

Technical Indicators

Market Signals
Indicator
SCOR
MURA
Relative Strength Index (RSI) 53.81 39.29
Support Level $6.40 $2.06
Resistance Level $7.10 $2.10
Average True Range (ATR) 0.43 0.01
MACD 0.07 -0.01
Stochastic Oscillator 84.85 19.38

Price Performance

Historical Comparison
SCOR
MURA

About SCOR comScore Inc.

comScore Inc is a United States-based information and analytics company that measures advertising, content, and the consumer audiences of each across media platforms. The platforms it measures include televisions, mobile devices, computers, tablets, CTV devices, and movie theaters. The company generates almost all its revenue from the United States, followed by Europe, Latin America, Canada, and other regions. It provides solutions for the automotive, digital media, financial services, pharmaceutical, retail, technology, travel, and other industries.

About MURA Mural Oncology plc

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

Share on Social Networks: